Eli Lilly Is Sitting at Its 52-Week High and the Momentum Says It's Going Higher

Signal: BUY | Score: 65.49/100

Lilly just reported $23 billion in quarterly revenue, raised full-year guidance, and got an FDA Breakthrough Therapy designation, all in the span of two weeks. The stock is hovering just below its all-time high. That is not a coincidence, and it is not time to sit this one out.

The Setup

LLY is trading at $1,286 with a 52-week high of $1,292.65, meaning it is within 0.5% of breaking out to new all-time highs. The momentum score of 79/100 is the strongest reading in this composite, and an RSI of 65.85 confirms the stock has room to run without being overextended. This is a trend continuation setup, not a speculative bet. The stock has nearly doubled off its 52-week low of $685 and is now coiling right at resistance. A clean break above $1,292 opens up a much larger move.

The Catalyst

The catalysts here are stacked and recent. On August 5, Lilly dropped Q2 earnings that showed 48% revenue growth year-over-year and immediately raised full-year guidance to $87 billion in revenue and $36.50 in EPS. Mounjaro and Zepbound are the engines, and supply is finally catching up with demand. Two days earlier, on August 3, the FDA granted Breakthrough Therapy designation to olomorasib for KRAS G12C-mutant pancreatic cancer, a notoriously hard-to-treat cancer with almost no good options. That is meaningful pipeline optionality that the market has not fully priced in. On top of that, Lilly has been aggressively expanding GLP-1 access through the Medicare GLP-1 Bridge Program and cracking down on the illegal retatrutide black market, which protects the commercial moat around its obesity franchise.

Bull Case

Guidance momentum is real. A $87B revenue target at 14x price-to-sales still looks reasonable when you consider forward PE drops to 27x, which is in line with Lilly's growth rate (PEG of 1.48).
The pipeline adds free upside. Olomorasib, Alzheimer's programs, and additional GLP-1 indications are not baked into current estimates, giving multiple shots on goal through 2027.
Analyst consensus target is $1,311. That is a near-term target, and Lilly has a history of outpacing street estimates.

Bear Case

Valuation is not cheap. Price-to-book at 33.8x and debt-to-equity at 162 mean any miss or guidance cut could get punished hard.
Pricing risk is real. Any movement on drug pricing legislation or Medicare negotiation expansion could pressure GLP-1 revenues faster than expected.

The Trade

Entry: $1,286
Target: $1,400
Stop Loss: $1,200
Risk/Reward: 1:1.3
Timeframe: 60 to 90 days

*This is one person's analysis, not financial advice. Always do your own research.*